ReviewManagement of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis
Introduction
The association between venous thromboembolism and cancer is well recognised.1 A prothrombotic state is present in many cancers as a result of an increase in procoagulants, such as tissue factor, cancer procoagulant, and factor VIIa, and hypercoaguability increases as the cancer progresses.2, 3, 4 Up to 15% of patients with cancer develop symptomatic venous thromboembolism (figure 1) that needs anticoagulation, and these patients have a poorer prognosis than those without venous thromboembolism; only 12% of patients with cancer and venous thromboembolism survive beyond 1 year.5, 6, 7 The prevalence of asymptomatic venous thromboembolism seems to increase with cancer progression. Asymptomatic deep-vein thrombosis can be present in half of hospice inpatients,8 and pulmonary embolism is noted in 30–50% of patients with cancer at post mortem.9, 10
Venous thromboembolism is generally treated by anticoagulation, initially with low-molecular-weight heparin (LMWH) followed by vitamin K antagonists, such as warfarin, for 3–6 months.11 The aim of this treatment is to prevent propagation of the existing deep-vein thrombosis and secondary prevention of further venous thromboembolism. However, compared with the general medical population, the treatment of venous thromboembolism in patients with cancer is more challenging, especially in advanced disease. An increased risk of recurrent thrombosis or bleeding while on warfarin has been extensively documented in patients with cancer.12, 13, 14, 15, 16, 17 Recent studies have consequently looked at the LMWHs as alternative long-term anticoagulants in this setting.18, 19, 20, 21 Current clinical guidelines consequently recommend LMWH for the long-term treatment of cancer-related venous thromboembolism in preference to warfarin.22, 23, 24, 25 However, such recommendations do not seem to be based on a formal systematic review and meta-analysis of the published work. Furthermore, many studies have investigated the management of venous thromboembolism in the general cancer population, involving patients who are receiving active treatment; therefore, their findings might not be fully transferable to patients within the palliative-care setting.
To help develop practice guidelines applicable to patients with advanced cancer across the entire spectrum of performance status and prognosis, the Thrombosis Taskgroup of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland has done this systematic review. The search for evidence was expanded beyond randomised controlled trials, and the data were pooled for meta-analysis where possible.
Section snippets
Methods
We searched Medline, The Cochrane Library, Embase, CINAHL, the British Nursing Index, AMED, Web of Science, and SCOPUS for papers published between January, 1966, and December, 2006, by use of the search terms “neoplasms”, “palliative care”, “thromboembolism”, and “anticoagulants”. There were no language or location restrictions. A hand search was done of the journals Palliative Medicine, Progress in Palliative Care, Journal of Pain and Symptom Management, and Journal of Supportive Oncology for
Results
Our search identified 5884 references. Only studies that reported anticoagulant treatment in patients with advanced cancer, and provided sufficient data on study design, participants and outcomes, were selected for closer reading. Two reviewers (SIRN and MJJ) independently selected 35 papers for review.12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 Of these papers, six were excluded because the study
Discussion
Increasing treatment options and better supportive care are leading to improved survival for patients with cancer, However, this increased survival means that the management of venous thromboembolism in patients with cancer is likely to be a frequent challenge for physicians Patients with advancing metastatic cancer are at the greatest risk of venous thromboembolism and, when receiving anticoagulation treatment, these patients have a high risk of recurrent venous thromboembolism and bleeding
References (55)
- et al.
Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor
Lancet
(1995) - et al.
The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer
Clin Oncol (R Coll Radiol)
(1999) - et al.
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
Blood
(2002) - et al.
Long-term low-molecular weight heparin versus usual care in proximal-vein thrombosis patients with cancer
Am J Med
(2006) - et al.
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest
(2004) - et al.
Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM)
Crit Rev Oncol Hematol
(2006) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study
J Thromb Haemost
(2004) - et al.
[Classical anticoagulant treatment of venous thromboembolic disease in cancer patients. Apropos of a retrospective study of 71 patients]
Rev Med Interne
(1996) - et al.
Anticoagulation therapy for VTE in patients with gynaecologic malignancy
Am J Obstet Gynecol
(1983)
Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis
Ann Oncol
Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota
Mayo Clin Proc
Vena cava filters in cancer patients: experience with 50 patients
Clinics
Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement
Ann Vasc Surg
Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis
J Thromb Haemost
Rules of evidence and clinical recommendations on the use of antithrombotic agents
Chest
Phlegmasia alba dolens
Abnormal coagulation and deep venous thrombosis in patients with advanced cancer
Clin Lab Haematol
Coagulation proteases and human cancer
Biochem Soc Trans
Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management
Semin Thromb Hemost
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data
Medicine (Baltimore)
Prognosis of cancers associated with venous thromboembolism
N Engl J Med
Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis
Am J Cancer
Causes of death in cancer patients
J Med
Guidelines on oral anticoagulation (warfarin): third edition—2005 update
Br J Haematol
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis
J Clin Oncol
Bleeding complications from warfarin anticoagulation in patients with malignancy
J Med
Cited by (95)
Morbidity Following Pulmonary Embolism Hospitalization- Contributing Factors and Outcomes
2024, Journal of Cardiothoracic and Vascular AnesthesiaTreatment of cancer-associated venous thromboembolism in patients under palliative care
2024, Archives of Cardiovascular DiseasesComplications of disease and therapy
2023, DiSaia and Creasman Clinical Gynecologic OncologyAmerican Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer
2021, Blood AdvancesCitation Excerpt :Different DOACs have different drug-drug interactions. We identified 11 systematic reviews addressing this question.304-313 From these reviews, we identified 8 eligible RCTs that fulfilled our inclusion criteria and measured outcomes relevant to this question.314-319
Venous thromboembolism in palliative care patients: what do we know?
2020, Thrombosis ResearchCitation Excerpt :There are a myriad of clinical guidelines to inform the general management of CAT and these, along with several guidance or consensus documents, also cover special circumstances such as thrombocytopenia, bleeding and thrombosis recurrence [4–6]. Only one has looked specifically at the palliative care population but based its recommendations on extrapolated data from healthier populations [7]. This reflects the dearth of high-quality, population-specific data on the subject.
- *
(Thrombosis Taskgroup)